US Stock Market Closed

Dashboard

Dicerna Pharmaceuticals, Inc. (DRNA)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity
Analyst Opinion

H

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.

CEO

Douglas M. Fambrough

Employees

187

Industry

Digestive System Biopharmaceuticals

Sector

Healthcare

Headquarters

Lexington

Exchange

NASDAQ

Summary Stats

Market Cap

2.99B

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 9 analysts

High

$45.00

Average

$35.00

Low

$25.00

Ratings calculated by 11 analysts

Buy

11

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2021

Last Earnings

Above by $0.24

Actual

-$0.22 +52.2%

Consensus

-0.46

Report Date

Year Ago

-0.29

Year Ago Change %

Up 24%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites